GHRH and non-Hodgkin lymphoma: Experiments modeling non-Hodgkin’s Lymphoma in cell lines and tumors xenografted into nude mice showed remarkable efficacy for GHRH antagonism therapy, further cementing the assumption of tumor growth inhibition as a direct effect of GHRH antagonism on malignant lymphoma cells and showcasing a novel means of achieving remission [26].